|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||







Departments of
*
Hematology-Oncology and
Pathology, St. Jude Childrens Research Hospital, and
Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38105; and
Childrens University Hospital, Tuebingen, Germany
In HLA-nonidentical bone marrow transplantation, we studied the characteristics of donor NK cells, recipient leukemia cells, and the cytokine environment that predict the antileukemia effects of allogeneic NK cells. We found that the risk of relapse in pediatric patients with hematologic malignancies was best predicted by a model taking into consideration the presence of inhibitory killer cell Ig-like receptors (KIRs) on the donors NK cells and the absence of corresponding KIR ligand in the recipients HLA repertoire (a receptor-ligand model). The risk of relapse was prognosticated less precisely by the Perugia donor-recipient KIR ligand-ligand mismatch model or by a natural cytotoxicity model. In contrast to the ligand-ligand model, we found that the new receptor-ligand model was accurate when analysis was applied to patients with lymphoid malignancy. These findings corroborate our observations that the recipients KIR repertoire, which was derived from highly purified, HLA-disparate CD34+ cells, resumed a donor-specific pattern within 3 mo of transplantation, but did not correlate evidently with the donor or recipient ligand repertoire. In an in vitro assay and an in vivo mouse model, human NK cell cytotoxicity toward human leukemia cells with 11q23 chromosomal rearrangement increased with the number of receptor-ligand mismatch pairs or prestimulation with IL-12 and IL-18. These findings provide new insights into the determinants of antileukemia effects of allogeneic NK cells and therapeutic strategies.
Related articles in The JI:
This article has been cited by other articles:
![]() |
M. Stern, L. Ruggeri, A. Mancusi, M. E. Bernardo, C. de Angelis, C. Bucher, F. Locatelli, F. Aversa, and A. Velardi Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor Blood, October 1, 2008; 112(7): 2990 - 2995. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Stern, L. Ruggeri, M. Capanni, A. Mancusi, and A. Velardi Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1 Blood, August 1, 2008; 112(3): 708 - 710. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shi, G. J. Tricot, T. K. Garg, P. A. Malaviarachchi, S. M. Szmania, R. E. Kellum, B. Storrie, A. Mulder, J. D. Shaughnessy Jr, B. Barlogie, et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma Blood, February 1, 2008; 111(3): 1309 - 1317. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Diermayr, H. Himmelreich, B. Durovic, A. Mathys-Schneeberger, U. Siegler, U. Langenkamp, J. Hofsteenge, A. Gratwohl, A. Tichelli, M. Paluszewska, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities Blood, February 1, 2008; 111(3): 1428 - 1436. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Chewning, C. N. Gudme, K. C. Hsu, A. Selvakumar, and B. Dupont KIR2DS1-Positive NK Cells Mediate Alloresponse against the C2 HLA-KIR Ligand Group In Vitro J. Immunol., July 15, 2007; 179(2): 854 - 868. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ruggeri, A. Mancusi, M. Capanni, E. Urbani, A. Carotti, T. Aloisi, M. Stern, D. Pende, K. Perruccio, E. Burchielli, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood, July 1, 2007; 110(1): 433 - 440. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Miller, S. Cooley, P. Parham, S. S. Farag, M. R. Verneris, K. L. McQueen, L. A. Guethlein, E. A. Trachtenberg, M. Haagenson, M. M. Horowitz, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT Blood, June 1, 2007; 109(11): 5058 - 5061. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Fischer, H. Ottinger, S. Ferencik, M. Sribar, M. Punzel, D. W. Beelen, M. A. Schwan, H. Grosse-Wilde, P. Wernet, and M. Uhrberg Relevance of C1 and C2 Epitopes for Hemopoietic Stem Cell Transplantation: Role for Sequential Acquisition of HLA-C-Specific Inhibitory Killer Ig-Like Receptor J. Immunol., March 15, 2007; 178(6): 3918 - 3923. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Fujii, J. D. Trudeau, D. T. Teachey, J. D. Fish, S. A. Grupp, K. R. Schultz, and G. S. D. Reid In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides Blood, March 1, 2007; 109(5): 2008 - 2013. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mullally and J. Ritz Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation Blood, February 15, 2007; 109(4): 1355 - 1362. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Triplett, R. Handgretinger, C.-H. Pui, and W. Leung KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia Blood, February 1, 2006; 107(3): 1238 - 1239. [Full Text] [PDF] |
||||
![]() |
M. Thomas, A. Gessner, H.-P. Vornlocher, P. Hadwiger, J. Greil, and O. Heidenreich Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells Blood, November 15, 2005; 106(10): 3559 - 3566. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Imai, S. Iwamoto, and D. Campana Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells Blood, July 1, 2005; 106(1): 376 - 383. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Hsu, C. A. Keever-Taylor, A. Wilton, C. Pinto, G. Heller, K. Arkun, R. J. O'Reilly, M. M. Horowitz, and B. Dupont Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes Blood, June 15, 2005; 105(12): 4878 - 4884. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Leung, R. Iyengar, B. Triplett, V. Turner, F. G. Behm, M. S. Holladay, J. Houston, and R. Handgretinger Comparison of Killer Ig-Like Receptor Genotyping and Phenotyping for Selection of Allogeneic Blood Stem Cell Donors J. Immunol., May 15, 2005; 174(10): 6540 - 6545. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Pende, G. M. Spaggiari, S. Marcenaro, S. Martini, P. Rivera, A. Capobianco, M. Falco, E. Lanino, I. Pierri, R. Zambello, et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112) Blood, March 1, 2005; 105(5): 2066 - 2073. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |